Mild cognitive impairment and new medications for Alzheimer's disease
On-demand recorded 20 Aug 2024
The new medications for Alzheimer's disease appear to work best in people with mild symptoms. It's therefore important that GPs recognise the importance of identifying mild cognitive impairment and try to identify patient eligibility for these medications. Careful selection of individuals will be necessary to avoid unnecessary waits or false hopes that could be raised by referring people who do not meet eligibility criteria.
This webinar will look at the identification of the patients with MCI in terms of diagnosis, and will use a case study to evaluate how a GP might then identify and discuss referral for medications.
The webinar will also review the latest understanding of how blood biomarkers may assist in the earlier diagnosis of MCI related to Alzheimer's Disease pathology.
Learning outcomes
- Describe the key features of Mild Cognitive Impairment
- Outline the pathway to new monoclonal antibodies
- Discuss how blood biomarkers may be used in improving diagnostic accuracy of Alzheimer's Disease
This event is part of RACGP Specific Interests and Dementia Training Australia - 2024 webinar series. Events in this series are:
Presenters
Dr Steph Daly
Dr Daly is a GP specialist in dementia. She is a Fellow of the Royal College of General Practitioners and completed post-graduate training in Dementia Studies at the University of Bradford (UK). Since moving to Australia she has become an advocate for patients living with dementia and facilitated her practice to becoming one of the first dementia-friendly, and Dementia Australia approved, GP clinics in Australia.
Dr Daly established and coordinates the Dementia Subgroup of RACGP Specific Interests Aged Care.
Dr Rebecca Moore
Medical educator – Dementia Training Australia
Dr Moore is a GP in Newcastle with a special interest in geriatrics and dementia. She has completed a Masters of Dementia, through the Wicking Research and Education Centre, University of Tasmania.